Suchergebnisse - "D'Arcangelo, Manolo"

PubPharm (32)

1

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

enthalten in: The New England journal of medicine | 2023

von Zhou, C. | Solomon, B. | Loong, H. | +122

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF8. - PMID 37874126

2

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

enthalten in: Journal of clinical pharmacology | 2023

von Hanley, M. | D'Arcangelo, M. | Felip, E. | +5

3

A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐ Positive or ROS1‐Positive Solid Tumors

enthalten in: The Journal of Clinical Pharmacology | 2023

von Hanley, M. | D'Arcangelo, M. | Felip, E. | +5

4

Pralsetinib in RET fusion-positive non-small-cell lung cancer : A real-world data (RWD) analysis from the Italian expanded access program (EAP)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Passaro, A. | Russo, G. | Passiglia, F. | +21

5

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC : The BEVERLY Multicenter Randomized Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Piccirillo, M. | Bonanno, L. | Garassino, M. | +30

6

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

enthalten in: The New England journal of medicine | 2022

von Forde, P. | Spicer, J. | Lu, S. | +127

CommentIn: N Engl J Med. 2022 May 26;386(21):2050-2051. - PMID 35403840

7

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma : A Large Multicenter Italian Study

enthalten in: Cancers | 2022

von Basso, U. | Paolieri, F. | Rizzo, M. | +18

8

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer : Interplay and Prognostic Effects

enthalten in: Frontiers in cell and developmental biology | 2021

von Bravaccini, S. | Bronte, G. | Petracci, E. | +8

9

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Subbiah, V. | Paz-Ares, L. | Besse, B. | +31

10

Lurbinectedin as second-line treatment for patients with small-cell lung cancer : a single-arm, open-label, phase 2 basket trial

enthalten in: The Lancet. Oncology | 2020

von Trigo, J. | Subbiah, V. | Besse, B. | +30

CommentIn: Lancet Oncol. 2020 May;21(5):605-607. - PMID 32224305